NCT07583823 Elevated Rate Pacing of Cardiac Amyloidosis
| NCT ID | NCT07583823 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Minnesota |
| Condition | Cardiac Amyloidosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-10-10 |
| Primary Completion | 2026-12-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2025-10-10 with a primary completion date of 2026-12-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.
Eligibility Criteria
Inclusion Criteria: * Adults 18 and older * Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee * Implanted Cardiac Pacemaker (+/- Defibrillator) * Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation * Non-dilated left ventricle by echocardiography * Ability to provide written consent * English Speaking Exclusion Criteria: * Paced QRS duration of \>150 ms (indicator for pacing mediated dyssynchrony) * Dilated left ventricle
Contact & Investigator
Valmiki Maharaj
PRINCIPAL INVESTIGATOR
University of Minnesota
Frequently Asked Questions
Who can join the NCT07583823 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiac Amyloidosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07583823 currently recruiting?
Yes, NCT07583823 is actively recruiting participants. Contact the research team at payne324@umn.edu for enrollment information.
Where is the NCT07583823 trial being conducted?
This trial is being conducted at Minneapolis, United States.
Who is sponsoring the NCT07583823 clinical trial?
NCT07583823 is sponsored by University of Minnesota. The principal investigator is Valmiki Maharaj at University of Minnesota. The trial plans to enroll 10 participants.